Adamis Laboratories is a specialty pharmaceutical company. Adamis Labs has a sales force and a small base of established prescription products that provide the foundation for rapid growth driven by new products. Three new products are currently under development, the first of which is targeted for release in the fourth quarter of 2008 with the next following about 16 months later. Adamis Viral Therapies is focused on developing patented vaccine technology that has the potential to provide protection against a number of different viral infectious agents. The first target is avian influenza. Avian flu is a particularly good initial clinical application because there is a large potential demand and the time to commercialization is relatively short, because is falls under bio-defense. Adamis hopes to initial clinical trials in the United States within the next 12-18 months and to be able to fully commercialize the anti-viral technology in about four years. Subsequent disease targets may include therapeutic vaccines for Hepatitis C and Human Papilloma Virus (HPV).
|